Table 2.
Therapeutic effect of distinct DC subsets alone in the prolongation of transplant survival and prevention of autoimmune disease
| DC subset | Condition | DC source | Therapeutic effect | Reference |
|---|---|---|---|---|
| Transplantation | ||||
| Immature donor myeloid (CD8α−) DC | Cardiac allograft | In vitro-generated | Prolonged graft survival | [49] |
| Immature donor myeloid DC (GMlowDC) | Cardiac allograft | In vitro-generated | Indefinite (>100 days) graft survival | [50] |
| CD205+B220+CD19 donor liver-derived DC | Cardiac allograft | In vitro-generated | Prolonged graft survival | [32] |
| Immature or mature ‘lymphoid – related’ CD8α+ donor DC† | Cardiac allograft | Freshly isolated | Prolonged graft survival | [120] |
| Autoimmune disease | ||||
| Myeloid (CD8α−) DC | Autoimune diabetes (NOD* mouse) | Freshly isolated from pancreatic lymph node | Prevention of diabetes | [77,78] |
| Mature myeloid DC | Autoimmune diabetes (NOD mouse) | In vitro generated | Prevention of diabetes, induction of Th2 response | [79,82] |
| ‘Semi-mature’ DC | EAE† (C57BL/6 mice) | In vitro generated-matured with TNF-α | Prevention of EAE, induction of IL-10-producing T cells | [26] |
| ‘EAE’-DC | EAE (Lewis rats) | In vitro generated from rats with EAE | Prevention of EAE and resistance to subsequent challenge | [88] |
| Splenic DC | EAMG‡ (Lewis rats) | Freshly isolated, exposed to TGFβ | Prevention of EAMG, reduced levels of specific antibody | [92] |
*
Non-obese diabetic;
†
experimental allergic encephalomyelitis;
‡
experimental autoimmune myasthenia gravis.